Acute Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Acute Leukemia

MalaCards integrated aliases for Acute Leukemia:

Name: Acute Leukemia 11 28 53 14 36 16 71 75
Stem Cell Leukaemia 11 33
Acute Leukaemia of Unspecified Cell Type Without Mention of Remission 33
Acute Undifferentiated Leukemia 71
Undifferentiated Leukaemia 33
Undifferentiated Leukemia 71
Blast Cell Leukaemia 33
Stem Cell Leukemia 11
Blastic Leukaemia 33
Acute Leukemias 14
Blast Leukaemia 33


External Ids:

Disease Ontology 11 DOID:12603
ICD9CM 34 208.0
NCIt 49 C9300
SNOMED-CT 68 24072005
ICD11 33 962107653
UMLS 71 C0085669 C0280141 C1378511

Summaries for Acute Leukemia

Disease Ontology: 11 A lymphoid leukemia that occurs when a hematopoietic stem cell undergoes malignant transformation into a primitive, undifferentiated cell with abnormal longevity producing large numbers of white blood cells to be produced and enter the blood stream.

MalaCards based summary: Acute Leukemia, also known as stem cell leukaemia, is related to acute biphenotypic leukemia and leukemia, acute lymphoblastic. An important gene associated with Acute Leukemia is KMT2A (Lysine Methyltransferase 2A), and among its related pathways/superpathways are Nervous system development and PI3K-Akt signaling pathway. The drugs Busulfan and Rasburicase have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Reduced mammosphere formation

Wikipedia: 75 Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original... more...

Related Diseases for Acute Leukemia

Diseases in the Leukemia family:

Chronic Leukemia Acute Leukemia
Subacute Leukemia

Diseases related to Acute Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1047)
# Related Disease Score Top Affiliating Genes
1 acute biphenotypic leukemia 33.4 PAX5 KMT2A KIT FLT3 ETV6 DNTT
2 leukemia, acute lymphoblastic 32.7 WT1 TCF3 RUNX1 PBX1 PAX5 MTHFR
3 leukemia 32.6 WT1 TCF3 STMN1 RUNX1 PBX1 MTHFR
4 leukemia, acute myeloid 32.6 WT1 TCF3 RUNX1 PBX1 PAX5 KRAS
5 mixed phenotype acute leukemia with t 32.5 KMT2A FLT3
6 mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2) 32.4 KMT2A FLT3
7 acute myeloblastic leukemia with maturation 32.4 KIT FLT3
8 mixed phenotype acute leukemia, t/myeloid 32.3 KMT2A FLT3
9 acute megakaryocytic leukemia 32.3 RUNX1 KMT2A KIT JAK2 FLT3 CEBPA
10 chronic leukemia 32.3 WT1 KIT JAK2 FLT3 ETV6
11 myelodysplastic syndrome 32.3 WT1 RUNX1 KRAS KMT2A KIT JAK2
12 acute myelomonocytic leukemia 32.3 RUNX1 KMT2A KIT FLT3 ETV6 DNTT
13 lymphoblastic lymphoma 32.2 PAX5 KRAS KMT2A DNTT
14 acute promyelocytic leukemia 32.2 WT1 RUNX1 KRAS KMT2A KIT FLT3
15 precursor t-cell acute lymphoblastic leukemia 31.9 KMT2A FLT3 ETV6 DNTT
16 neutropenia 31.8 KRAS JAK2 FLT3 CSF3 CEBPA
17 myeloid leukemia 31.8 WT1 RUNX1 KMT2A KIT JAK2 FLT3
18 leukemia, chronic myeloid 31.7 WT1 RUNX1 KRAS KMT2A KIT JAK2
19 b-lymphoblastic leukemia/lymphoma 31.7 TCF3 PBX1 PAX5 KMT2A KIT FLT3
20 down syndrome 31.7 RUNX1 MTHFR KMT2A JAK2 FLT3 ETV6
21 childhood acute lymphocytic leukemia 31.6 RUNX1 MTHFR KMT2A GSTM1 FLT3 ETV6
22 hematologic cancer 31.6 WT1 RUNX1 PAX5 KMT2A KIT JAK2
23 childhood leukemia 31.6 WT1 TCF3 PBX1 KMT2A KIT FLT3
24 pancytopenia 31.6 RUNX1 KMT2A KIT FLT3 CSF3
25 deficiency anemia 31.5 KIT JAK2 GSTM1 FLT3 CSF3
26 myeloproliferative neoplasm 31.4 RUNX1 KMT2A KIT JAK2 FLT3 ETV6
27 monocytic leukemia 31.4 RUNX1 KMT2A CSF3 CREBBP AFF1
28 myeloma, multiple 31.4 TCF3 PAX5 KRAS JAK2 FLT3 CSF3
29 lymphoma, non-hodgkin, familial 31.4 PAX5 KMT2A JAK2 FLT3 ETV6 DNTT
30 myeloid sarcoma 31.4 KMT2A KIT FLT3 DNTT
31 myelofibrosis 31.4 WT1 RUNX1 KIT JAK2 FLT3 ETV6
32 acute erythroid leukemia 31.3 KIT JAK2 FLT3 CEBPA
33 thrombocytopenia 31.3 RUNX1 PAX5 MTHFR KIT JAK2 FLT3
34 leukemia, acute monocytic 31.3 KMT2A FLT3 CREBBP
35 wilms tumor 1 31.3 WT1 KRAS KIT FLT3
36 burkitt lymphoma 31.3 TCF3 PAX5 DNTT CSF3
37 polycythemia vera 31.3 KIT JAK2 ETV6 CSF3
38 leukemia, chronic lymphocytic 31.2 PAX5 KRAS KMT2A KIT JAK2 FLT3
39 adult acute lymphocytic leukemia 31.2 TCF3 PBX1 PAX5 MTHFR KMT2A ETV6
40 essential thrombocythemia 31.1 KIT JAK2 FLT3 ETV6 CSF3
41 exanthem 31.1 KRAS KIT CSF3
42 childhood acute myeloid leukemia 31.0 WT1 KMT2A KIT FLT3 CEBPA
43 chronic myelomonocytic leukemia 31.0 RUNX1 KRAS KIT JAK2 FLT3 ETV6
44 central nervous system leukemia 31.0 PBX1 KMT2A ETV6 AFF1
45 mastocytosis 30.8 KIT JAK2 FLT3
46 myeloproliferative syndrome, transient 30.8 KMT2A KIT FLT3
47 blood platelet disease 30.8 RUNX1 KIT JAK2 FLT3 CSF3
48 neutrophilia, hereditary 30.7 JAK2 FLT3 CSF3
49 severe congenital neutropenia 30.6 RUNX1 JAK2 CSF3 CEBPA
50 medulloblastoma 30.6 STMN1 PAX5 KIT JAK2 CSF3 CREBBP

Comorbidity relations with Acute Leukemia via Phenotypic Disease Network (PDN):

Deficiency Anemia Neutropenia

Graphical network of the top 20 diseases related to Acute Leukemia:

Diseases related to Acute Leukemia

Symptoms & Phenotypes for Acute Leukemia

GenomeRNAi Phenotypes related to Acute Leukemia according to GeneCards Suite gene sharing:

25 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.29 WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.29 FLT3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.29 FLT3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.29 KRAS
5 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.29 WT1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.29 DNTT
7 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.29 DNTT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-145 10.29 DNTT WT1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.29 DNTT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.29 WT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.29 DNTT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.29 DNTT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.29 FLT3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-182 10.29 DNTT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.29 WT1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.29 KRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.29 FLT3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.29 WT1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.29 WT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.29 WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-48 10.29 CEBPA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.29 KRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.29 FLT3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-72 10.29 CEBPA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.29 DNTT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.29 WT1
27 no effect GR00402-S-1 10.21 AFF1 BAALC CEBPA CREBBP CSF3 DNTT
28 no effect GR00402-S-2 10.21 AFF1 BAALC CEBPA CREBBP CSF3 DNTT
29 Reduced mammosphere formation GR00396-S 9.56 CEBPA CSF3 ETV6 GSTM1 KMT2A KRAS

MGI Mouse Phenotypes related to Acute Leukemia:

45 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.48 CEBPA CREBBP DNTT ETV6 FLT3 GSTM1
2 normal MP:0002873 10.45 CEBPA CREBBP DNTT ETV6 JAK2 KIT
3 nervous system MP:0003631 10.4 AFF1 CREBBP GSTM1 JAK2 KIT KMT2A
4 growth/size/body region MP:0005378 10.4 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
5 neoplasm MP:0002006 10.39 CEBPA CREBBP ETV6 FLT3 JAK2 KIT
6 liver/biliary system MP:0005370 10.35 CEBPA CREBBP ETV6 JAK2 KIT KMT2A
7 no phenotypic analysis MP:0003012 10.34 AFF1 CEBPA ETV6 FLT3 KIT KMT2A
8 cellular MP:0005384 10.32 CEBPA CREBBP ETV6 FLT3 GSTM1 JAK2
9 immune system MP:0005387 10.31 AFF1 CEBPA CREBBP CSF3 DNTT ETV6
10 endocrine/exocrine gland MP:0005379 10.29 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
11 renal/urinary system MP:0005367 10.24 CEBPA CSF3 ETV6 KIT KMT2A KRAS
12 behavior/neurological MP:0005386 10.21 AFF1 CEBPA CREBBP DNTT GSTM1 JAK2
13 cardiovascular system MP:0005385 10.2 CEBPA CREBBP ETV6 JAK2 KIT KMT2A
14 embryo MP:0005380 10.19 CREBBP ETV6 JAK2 KIT KMT2A KRAS
15 muscle MP:0005369 10.18 CEBPA CREBBP KIT KMT2A KRAS PBX1
16 limbs/digits/tail MP:0005371 10.1 CREBBP KIT KMT2A KRAS MTHFR PBX1
17 hematopoietic system MP:0005397 10.06 AFF1 CEBPA CREBBP CSF3 DNTT ETV6
18 reproductive system MP:0005389 10.02 AFF1 CEBPA JAK2 KIT KMT2A KRAS
19 hearing/vestibular/ear MP:0005377 10.01 GSTM1 KIT KMT2A KRAS PAX5 PBX1
20 skeleton MP:0005390 10 CREBBP ETV6 FLT3 JAK2 KIT KMT2A
21 respiratory system MP:0005388 9.97 CEBPA CREBBP JAK2 KIT KRAS PBX1
22 mortality/aging MP:0010768 9.83 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
23 integument MP:0010771 9.36 CEBPA CREBBP CSF3 ETV6 JAK2 KIT

Drugs & Therapeutics for Acute Leukemia

Drugs for Acute Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 347)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Busulfan Approved, Investigational Phase 4 55-98-1 2478
Rasburicase Approved, Investigational Phase 4 134774-45-1
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
Uric acid Investigational Phase 4 69-93-2 1175
Imatinib Mesylate Phase 4 220127-57-1
7 HH-GV-678 Phase 4
Oprelvekin Approved, Investigational Phase 2, Phase 3 145941-26-0
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
Coenzyme M Approved, Investigational Phase 3 3375-50-6 598 23662354
Clove Approved Phase 2, Phase 3 84961-50-2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
Ofloxacin Approved Phase 3 82419-36-1 4583
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
Nalbuphine Approved Phase 3 20594-83-6 5311304
Morphine Approved, Investigational Phase 3 57-27-2 5288826
Rituximab Approved Phase 3 174722-31-7
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
Tioguanine Approved Phase 3 154-42-7 2723601
Hydroxyurea Approved Phase 2, Phase 3 127-07-1 3657
Inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
Ifosfamide Approved Phase 3 3778-73-2 3690
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
Ichthammol Approved Phase 3 8029-68-3
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
Lenograstim Approved, Investigational Phase 3 135968-09-1
Mercaptopurine Approved Phase 3 50-44-2 667490
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
Asparaginase Escherichia coli Approved, Investigational Phase 3 9015-68-3
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
Pegaspargase Approved, Investigational Phase 3 130167-69-0
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
Picropodophyllin Approved, Investigational Phase 3 518-28-5, 477-47-4 10607 72435
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
Abatacept Approved Phase 3 332348-12-6
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
Vedolizumab Approved Phase 3 943609-66-3
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 450)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation Unknown status NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
2 Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants Unknown status NCT01339988 Phase 4 Busulfan/Cyclophosphamide
3 An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin¿s Lymphoma and Acute Leukemia Completed NCT04349306 Phase 4 RASBURICASE SR29142
4 Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever in Pediatric Acute Leukemia: Review of Temperature and Absolute Neutrophil Completed NCT04187755 Phase 4 Ceftazidime Injection;Cefepime Injection
5 Clinical Study of rATG Individualized Administration for Prevention of GVHD and Maintenance of GVL in Haploidentical Hematopoietic Stem Cell Transplantation. Recruiting NCT05634915 Phase 4 Individual ATG;ATG
6 Flumatinib Versus Imatinib Combined With Multiagent Chemotherapy for Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: A Prospective, Open-label,Randomized,Multi-center Clinical Trial Recruiting NCT05071482 Phase 4 Flumatinib;Imatinib
7 Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia in Patients With Acute Leukemia Receiving Chemotherapy Unknown status NCT02241031 Phase 2, Phase 3 thrombopoietin (TPO) and interleukin-11
8 Hypomethylating Agents + Donor Lymphocyte Infusion vs Donor Lymphocyte Infusion Preemptive Therapy Based on Minimal Residual Disease for Acute Leukemia Undergoing Allogenetic Hematopoietic Stem Cell Transplantation Unknown status NCT03662087 Phase 2, Phase 3
9 Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT03596892 Phase 2, Phase 3 Decitabine;Busulfan (BU);Cyclophosphamide (CY)
10 A Prospective, Multicenter Randomized Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in Children and Young Adults (<35 Years) With Acute Leukemia Remission Unknown status NCT01067300 Phase 3
11 A Phase I-II Pilot Clinical Trial of Safety and Efficacy of Personalized Targeted Preparative Regimen With Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation and Posttransplant Donor T- Cells Infusion in Children With Chemoresistаnt Acute Leukemia. Unknown status NCT04000698 Phase 3 Preparative regimen
12 Randomized Multicenter Trial of Two Transfusion Strategies for Patient Receiving Chemotherapy for Acute Leukemia or Hematopoietic Stem Cells With Medico-economic Evaluation of Cost Minimization. Unknown status NCT02461264 Phase 3 Single red blood packed cells Transfusion;Two packed red blood cells Transfusion
13 Oral Voriconazole vs IV Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction:A Prospective, Randomized, Clinical Trial. Unknown status NCT00624143 Phase 3 ORAL VORICONAZOLE and IV Amphotericin B
14 Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial Unknown status NCT01516580 Phase 3 Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
15 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
16 Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin)
17 A Phase III, Randomized, Multicentre Trial Comparing Allogeneic Filgrastim Mobilised Peripheral Blood Progenitor Cell Transplantation (PBPCT) With Allogeneic Bone Marrow Transplantation (BMT) in Patients With Acute Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT01020175 Phase 3
18 Clofarabine, Cyclophosfamide, And Etoposide For The Treatment Of Relapsed Or Resistant Acute Leukemia In Pediatric Patients Completed NCT01385891 Phase 2, Phase 3 Clofarabine VP 16 ciclophospahamide
19 A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Completed NCT01371656 Phase 3 levofloxacin
20 A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301; Progress II) Completed NCT02345850 Phase 3 Cyclophosphamide;Tacrolimus;Methotrexate
21 Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine Patient Controlled Analgesia (PCA) for Mucositis Pain in Pediatric Patients. A Prospective Randomized Double Blinded Clinical Trial Completed NCT03825887 Phase 3 Nalbuphine;Morphine
23 A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft Recruiting NCT05316701 Phase 3
24 Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3 Negative Acute Leukemia Recruiting NCT04674345 Phase 2, Phase 3 Sorafenib
25 Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia Patients Undergoing HSCT Recruiting NCT03799224 Phase 2, Phase 3 Decitabine;mBU/CY and ATG;mBU/CY
26 Comparing Post-Transplant Cyclophosphamide With Calcineurin Inhibitors as A GVHD Prophylaxis to Standard Care of Methotrexate and Calcineurin Inhibitors for Acute Leukemia Incorporating Patient Pharmacogenomics Profiling Recruiting NCT04314219 Phase 3 Cyclophosphamide 50mg;Methotrexate
27 Decitabine Plus mBU/CY for High Risk Acute Leukemia With Minimal Residual Disease Pre-HSCT Recruiting NCT03793517 Phase 2, Phase 3 Decitabine;mBU/CY and ATG;mBU/CY
28 A Phase III, Randomized, Clinical Trial Comparing Two Diets in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT) or Remission Induction Chemotherapy for Acute Leukemia and Myelodysplastic Syndrome (UF-BMT-LDND-101) Recruiting NCT03016130 Phase 3
29 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy Recruiting NCT03959085 Phase 3 Calaspargase Pegol-mknl;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine Sulfate
30 A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS) Recruiting NCT05457556 Phase 3 Busulfan;Cyclophosphamide;Fludarabine;Melphalan;Methotrexate;Mycophenolate Mofetil;Tacrolimus;Thiotepa
31 Evaluation of a Donor Testing Kit for the Prediction of Acute GVHD in Patient Receiving a Peripheral Blood Stem Cells Allograft- Predictor 2 Recruiting NCT03887156 Phase 2, Phase 3
32 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones Recruiting NCT03007147 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Dexrazoxane Hydrochloride;Doxorubicin;Etoposide;Ifosfamide;Imatinib Mesylate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisolone;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
33 A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients Recruiting NCT04446130 Phase 3 Decitabine combined with HAAG Regimen
34 A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies Active, not recruiting NCT02730299 Phase 3 NiCord® (omidubicel)
35 Extension of a Phase III Randomized Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen-HaploMUD-RIC-01 Active, not recruiting NCT03595800 Phase 3
36 A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune) Active, not recruiting NCT03959241 Phase 3 Tacrolimus;Methotrexate;Mycophenolate Mofetil;Cyclophosphamide
37 A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) Active, not recruiting NCT00557193 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Etoposide;Lestaurtinib;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
38 Interfant-21 International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia. Not yet recruiting NCT05327894 Phase 3 Blinatumomab
39 A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy Not yet recruiting NCT05602194 Phase 3 Calaspargase Pegol-mknl;Pegaspargase
40 Prospective Pilot Study of the Clinical Efficacy and Safety of the Method for Preventing a Graft-versus-host Disease Through the Agency of Using the Combination of Post-transplantation Cyclophosphamide With Abatacept, Vedolizumab and Calcineurin Inhibitor at Children and Young Adults With Hemoblastosis After Hematopoietic Stem Cell Transplantation From an Unrelated or Haploidentic Donor Not yet recruiting NCT05515029 Phase 3
41 A Phase 3 Randomised Double-Blinded Placebo-Controlled Study of Use of GnRHa During Chemotherapy for Fertility Protection of Young Women and Teenagers With Cancer Not yet recruiting NCT05328258 Phase 3 Triptorelin Embonate;Sodium Chloride solution 0.9%
42 TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia Terminated NCT00914628 Phase 3
43 Allogeneic Stem Cell Transplantation Using Mylotarg (CMA-676) Plus Nonmyeloablative Chemotherapy in Older or Medically Infirm Patients With High-Risk Acute Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or Myelodysplastic Syndrome (MDS) Terminated NCT00038805 Phase 2, Phase 3 Mylotarg
44 Effects of Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia Withdrawn NCT00943709 Phase 3 therapeutic insulin
45 Clinical Study of Genetically Modified Dendritic Cells Combining to Cytokine-Induced Killer Cells for Patients With Relapse Acute Leukemia After Allo-HSCT Unknown status NCT01956630 Phase 1, Phase 2
46 Multiple Consolidation Chemotherapy and DLI Prevent Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant and Achieving Complete Remission After Induction Chemotherapy and DLI Unknown status NCT03297528 Phase 2 donor lymphocyte infusion
47 Chemo Sensitization Before Hematopoietic Stem Cell Transplantation With a CXCR4 Antagonist in Patients With Acute Leukemia in Complete Remission: Pilot Study Unknown status NCT02605460 Phase 2 Busulfan;Cyclophosphamide;CXCR4 Antagonist
48 Phase I/II Study of PR104 in Subjects With Refractory/Relapsed Acute Leukemia Using Adaptive Dose Selection Unknown status NCT01037556 Phase 1, Phase 2 PR104
49 Allo-allo Tandem Matched Stem Cell Transplantation (AATT) for the Treatment of Patients With Refractory Acute Leukemia; a Feasibility Phase I/II Study Unknown status NCT00984412 Phase 1, Phase 2
50 Phase 2 Double-blind, Randomized, Placebo Controlled Clinical Trial for the Prevention of Oral Mucositis Using Sub-microbial Doses of Doxycycline Hyclate in Patients With Acute Leukemia Receiving Induction Chemotherapy Unknown status NCT01087476 Phase 2 Doxycycline hyclate

Search NIH Clinical Center for Acute Leukemia

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Acute Leukemia:
Promostem, mesenchymal stem cells for treatment of graft-versus-host disease

Genetic Tests for Acute Leukemia

Genetic tests related to Acute Leukemia:

# Genetic test Affiliating Genes
1 Acute Leukemia 28

Anatomical Context for Acute Leukemia

Organs/tissues related to Acute Leukemia:

MalaCards : Bone Marrow, Myeloid, T Cells, Bone, Nk Cells, Liver, Neutrophil

Publications for Acute Leukemia

Articles related to Acute Leukemia:

(show top 50) (show all 20677)
# Title Authors PMID Year
Bench to bedside targeting of FLT3 in acute leukemia. 53 62
20370649 2010
A role for PKR in hematologic malignancies. 53 62
20232306 2010
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. 53 62
20435628 2010
Targeting CREB for cancer therapy: friend or foe. 53 62
20370681 2010
Adenovirus-mediated stem cell leukemia gene transfer induces rescue of interstitial cells of Cajal in ICC-loss mice. 53 62
20165856 2010
Clinical correlation of circulating heat shock protein 70 in acute leukemia. 53 62
19800118 2010
Methylenetetrahydrofolate reductase gene polymorphisms: association with risk for pediatric acute lymphoblastic leukemia in north Indians. 53 62
20367562 2010
RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. 53 62
20181616 2010
Complex and cryptic chromosomal rearrangements involving the MLL gene in acute leukemia: a study of 7 patients and review of the literature. 53 62
20206559 2010
The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0. 53 62
20111912 2010
[Expression of CREB/Bcl-2 in bone marrow mononuclear cells of children with acute leukemia]. 53 62
20350424 2010
Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. 53 62
20072157 2010
Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice. 53 62
20007546 2010
Droplet-based gene expression analysis using a device with magnetic force-based-droplet-handling system. 53 62
20129107 2010
[FLT3 gene mutation and its prognostic implication in patients with acute leukemia.]. 53 62
20302766 2010
Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia. 53 62
20306249 2010
PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. 53 62
20145726 2010
Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia. 53 62
19935430 2010
Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. 53 62
19404640 2009
[Clinical significance of detecting serum erythropoietin in patients with leukemia]. 53 62
19923094 2009
Discrepant immunophenotypic characteristics between the lymph node and bone marrow in two mixed-phenotype acute leukemia patients. 53 62
19893347 2009
PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. 53 62
19507191 2009
Outcomes of CAG regimen for refractory biphenotypic acute leukemia patients. 53 62
19848320 2009
Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. 53 62
19530238 2009
New insights to the MLL recombinome of acute leukemias. 53 62
19262598 2009
Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. 53 62
19811333 2009
ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. 53 62
19635183 2009
Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity. 53 62
19605811 2009
Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. 53 62
19506298 2009
[Studies on the mutation and polymorphism of the TPMT gene in Chinese children with acute leukemia]. 53 62
20017316 2009
Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population. 53 62
19454497 2009
GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. 53 62
19212333 2009
Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. 53 62
19250671 2009
Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. 53 62
19411632 2009
DNA damage response as a biomarker in treatment of leukemias. 53 62
19411853 2009
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. 53 62
19279403 2009
High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. 53 62
19357396 2009
Detection of myeloperoxidase activity in primary leukemic cells by an enhanced chemiluminescent assay for differentiation between acute lymphoblastic and non-lymphoblastic leukemia. 53 62
19298796 2009
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia]. 53 62
19379589 2009
[Myeloproliferative diseases caused by JAK2 mutation]. 53 62
19489438 2009
Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis. 53 62
19151769 2009
HOXA9 is required for survival in human MLL-rearranged acute leukemias. 53 62
19056693 2009
Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. 53 62
19036706 2009
Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. 53 62
19202074 2009
Maternal acute lymphoctic leukemia with rearrangement of the mixed lineage leukemia gene occurring during pregnancy. 53 62
20139053 2009
Expression of lineage markers using real-time quantitative polymerase chain reaction (RT-qPCR) in normal and in leukemia bone marrow. 53 62
19327122 2009
A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. 53 62
18948576 2009
The role of myeloid growth factors in acute leukemia. 53 62
19176208 2009
New thrombopoietic growth factors. 53 62
19778863 2009
Panhandle PCR approaches to cloning MLL genomic breakpoint junctions and fusion transcript sequences. 53 62
19277575 2009

Variations for Acute Leukemia

Expression for Acute Leukemia

Search GEO for disease gene expression data for Acute Leukemia.

Pathways for Acute Leukemia

Pathways related to Acute Leukemia according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
5 11.76 KIT FLT3 CSF3
6 11.74 KRAS KIT JAK2
Show member pathways
Show member pathways
Show member pathways
11.24 KRAS JAK2 CSF3
12 11.09 TCF3 JAK2 CREBBP
13 10.63 FLT3 ETV6 CREBBP
Show member pathways
Show member pathways
10.47 RUNX1 PAX5

GO Terms for Acute Leukemia

Biological processes related to Acute Leukemia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 10.19 TCF3 STMN1 PBX1 PAX5 JAK2 FLT3
2 regulation of DNA-templated transcription GO:0006355 10.07 WT1 TCF3 RUNX1 PBX1 PAX5 KMT2A
3 positive regulation of DNA-binding transcription factor activity GO:0051091 10.03 TCF3 KIT JAK2 CSF3
4 B cell differentiation GO:0030183 10.01 TCF3 PAX5 KIT FLT3
5 visual learning GO:0008542 9.93 KIT KMT2A KRAS
6 regulation of cell population proliferation GO:0042127 9.92 PBX1 KIT FLT3 CEBPA
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.92 CSF3 FLT3 JAK2 KIT
8 hematopoietic stem cell proliferation GO:0071425 9.85 RUNX1 ETV6 CEBPA
9 myeloid progenitor cell differentiation GO:0002318 9.78 FLT3 KIT
10 positive regulation of transcription by RNA polymerase II GO:0045944 9.66 WT1 TCF3 RUNX1 PBX1 PAX5 KMT2A
11 cytokine-mediated signaling pathway GO:0019221 9.65 CEBPA CSF3 FLT3 JAK2 KIT
12 embryonic hemopoiesis GO:0035162 9.63 PBX1 KMT2A KIT
13 positive regulation of response to stimulus GO:0048584 9.51 KIT FLT3
14 positive regulation of protein modification process GO:0031401 9.49 KIT FLT3

Molecular functions related to Acute Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription cis-regulatory region binding GO:0000976 9.81 WT1 TCF3 RUNX1 PBX1 CEBPA
2 DNA-binding transcription factor binding GO:0140297 9.8 TCF3 PBX1 CREBBP CEBPA
3 DNA-binding transcription factor activity GO:0003700 9.73 CEBPA ETV6 PAX5 PBX1 RUNX1 TCF3
4 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.47 WT1 TCF3 RUNX1 PBX1 PAX5 ETV6

Sources for Acute Leukemia

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....